Hepatic lipogenesis enzymes and transcriptional regulators

The hepatic lipogenesis pathway describes the series of biochemical reactions in the liver that convert carbohydrates (such as glucose and fructose) into fatty acids and triglycerides for energy storage[2][3][4][5]. This process is tightly regulated by hormones (notably insulin) and nutrient status, and is controlled by specific enzymes (acetyl-CoA carboxylase, fatty acid synthase, etc.) and transcription factors (SREBP-1c, ChREBP, Liver X receptor)[1][4]. Dysregulation of this pathway is implicated in several metabolic diseases, notably non-alcoholic fatty liver disease, obesity, and insulin resistance[2][1][3]. The pathway is a major therapeutic target for metabolic syndrome and associated liver disorders, with efforts focused on inhibiting key enzymes or the transcriptional programs that drive excessive lipid synthesis and storage.

Other names

Hepatic lipogenesisLiver lipid synthesis pathwayDe novo lipogenesis (DNL)Lipogenic pathway

Enzyme inhibition (blocking ACC, FASN reduces fatty acid synthesis; decreases lipid accumulation) Transcription factor modulation (blocking/activating SREBP-1c or ChREBP influences enzyme expression and pathway activity) Insulin pathway modulation (affects lipogenic transcription and enzyme activity)